`(10) Patent No.:
`US 9,339,507 B2
`
`Olschewski et al.
`(45) Date of Patent:
`May 17, 2016
`
`USOO9339507B2
`
`(54) TREPROSTINIL ADMINISTRATION BY
`INHALATION
`
`(75)
`
`.
`.
`Inventors: Horst Olschewskl, Craz (AT), Robert
`Roselgnoa Chapel H111, NC (US); LeWIS
`J. Rubin, LaJolla, CA (US); Thomas
`schmehl Giessen
`Werner
`-
`’
`.
`’-
`Seeger, GIessen (DE), Carl Sterrltt,
`Weybrldge (GB); RObertVOSWIHCkeL
`GIessen (DE)
`
`(73) Assignee: United Therapeutics Corporation,
`-
`-
`Sllver Spnng’ MD (Us)
`.
`.
`.
`.
`Subject to any d1scla1mer, the term of th1s
`patent is extended or adjusted under 35
`U .S.C. 154(b) by 301 days.
`
`.
`( * ) Notlce:
`
`.
`(21) Appl‘ No“ 13/469354
`.
`Flledi
`
`(22)
`
`May11s2012
`
`(65)
`
`Prior Publication Data
`
`US 2012/0216801 A1
`
`Aug. 30, 2012
`
`_
`_
`Related US. Application Data
`.
`.
`.
`.
`.
`(60) D1V1slon of appllcatIOn No. 12/591,200, filed on NOV.
`12, 2009, thCh 1s a cont1nuat10n of applIcatIon No.
`11/748,205, filed on May 14, 2007.
`.
`.
`.
`.
`PrOVIslonal applIcatIon No. 60/800,016, filed on May
`15’ 2006‘
`
`(60)
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int- 0-
`A61K 31/192
`A6IP 9/12
`A61M11/00
`A61K 31/55 7
`A61K 9/00
`(52) US 0-
`CPC ............. .. A61K 31/557 (2013.01); A61K 9/008
`(2013.01);A61K 9/0078 (2013.01)
`(58) Field of Classification Search
`CPC ........................... .. A61K 31/557; A61K 9/008
`
`4,976,259 A
`4,984,158 A
`5,063,922 A
`5,080,093 A
`5,153,222 A
`5,234,953 A
`5,322,057 A
`5,361,989 A
`5,363,842 A
`5,497,763 A
`5,551,416 A
`5,727,542 A
`5,865,171 A
`2
`,
`,
`6,054,486 A
`6,123,068 A
`6,357,671 B1
`6,521,212 B1
`6,626,843 132
`6,756,033 B2
`6,765,117 B2
`6,803,386 B2
`6,809,223 B2
`7,172,557 B1
`7,199,157 B2
`7,384,978 B2
`7,417,070 B2
`7,544,713 132
`7,726,303 B2
`2003/0192532 A1
`2004/0063912 A1
`2004/0105819 A1
`2004/0149282 A1
`2004/0265238 A1
`2005/0165111 A1
`2005/0166913 A1
`2005/0183719 A1
`
`12/1990 Higson et al.
`1/1991 Hillsman
`11/1991 Hakkinen
`1/1992 Raabe et a1.
`10/1992 Tadepalli et 31.
`8/1993 Crow et al.
`6/1994 Raabe et al.
`11/1994 Merchat et a1.
`11/1994 Mishelevich et a1.
`3/1996 Lloyd et 31.
`9/1996 Stimpson et a1.
`3/1998 King
`2/1999 Cinquin
`(Sillibasaki
`eIman
`4/2000 Crow et al.
`9/2000 L1
`(1
`tal.
`3/2002 Ceaer:
`2/2003 Cloutier et 31.
`9/2003 Hillsman
`6/2004 Cloutier et a1.
`7/2004 Moriarty et a1.
`10/2004 Shorr et a1.
`10/2004 Moriarty et a1.
`2/2007 Parker
`4/2007 Wade et a1.
`6/2008 Phares et a1.
`8/2008 Phares et al.
`6/2009 Phares et 31.
`6/2010 Tyvoll et a1.
`10/2003 Hopkins
`4/2004 Blumberg et a1.
`6/2004 H 1
`t
`1.
`8/2004 111:1: a
`12/2004 Chaudry
`7/2005 Wade et al.
`8/2005 Sexton et a1.
`8/2005 Wuttke et al.
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`
`AU
`DE
`
`2/2000
`1999959533 B2
`6/2000
`19838711 Cl
`(Continued)
`
`OTHER PUBLICATIONS
`
`EPA Integrated Risk Information System (IRIS): data sheet for
`3-methylphenol (m-cresol). Accessed at http://wwwepagov/iris/
`subst/0301.htm on Mar. 9, 2014).*
`
`USPC ........................................................ .. 514/569
`See application file for complete search history.
`
`(Continued)
`
`(56)
`
`References Cited
`
`.
`.
`Primary Examzner 7 Jeffrey S Lundgren
`
`U~S~ PATENT DOCUMENTS
`
`Assistant Examiner 7 Sara E Townsley
`
`3,664,337 A
`4,001,650 A
`4,281,113 A
`
`4,306,075 A
`4,306,076 A
`2
`4:486:598 A
`4,495,944 A
`4,635,647 A
`4,668,814 A
`4,677,975 A
`4,683,330 A
`4,692,464 A
`4,708,963 A
`
`5/1972 Lindsey et 31,
`1/1977 Romain
`7/1981 Axen et a1.
`
`l2/l981 Aristoff
`12/1981 Nelson
`$283): et al.
`12/1984 Aristoff
`1/1985 Bilislion et al.
`1 1987 C 0 si
`5/1987 Aristoff
`7/1987 Edgar et al.
`7/1987 Aristoff
`9/1987 Skuballa et a1.
`11/1987 Skuballa et a1.
`
`(74) Attorney, Agent, or Firm 7 Foley & Lardner LLP
`
`(57)
`
`ABSTRACT
`
`Treprostinil can be administered using a metered dose
`inhaler. Such administration provides a greater degree of
`autonomy to patients. Also disclosed are kits that include a
`~
`~
`~
`~
`_
`metered dose Inhaler ContaInIng a pharmaceutIcal formula
`tlon conta1n1ngtreprost1ml.
`
`9 Claims, 12 Drawing Sheets
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 1 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 1 of 24
`
`
`
`US 9,339,507 B2
`Page 2
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2005/0282901 A1
`2006/0147520 A1
`2006/0201500 A1
`2008/0200449 A1
`2008/0280986 A1
`2009/0036465 A1
`2010/0076083 A1
`2010/0236545 A1
`2010/0282622 A1
`2012/0177693 A1
`
`12/2005 Phares et al.
`7/2006 Ruegg
`9/2006 Von Hollen et a1.
`8/2008 Olschewski et al.
`11/2008 Wade et a1.
`2/2009 Roscigno et al.
`3/2010 Olschewski et al.
`9/2010 Kern
`1 1/20 10 Phares
`7/2012 Cipolla et a1.
`
`FOREIGN PATENT DOCUMENTS
`
`DE
`FR
`JP
`W0
`WO
`
`19934582 A1
`2783431 A1
`2003-522003 A
`WO 01/58514 A1
`W001/85241 A1
`
`1/2001
`3/2000
`7/2003
`8/2001
`11/2001
`
`OTHER PUBLICATIONS
`
`Abe et al., “Effects of inhaled prostacyclin analogue on chronic
`hypoxic pulmonary hypertension,” J. Cardiovascular Pharmacology,
`2001, 37, 239 251.
`Aradigm Corporation news release Oct. 24, 2005, “Aradigm and
`United Therapeutics Sign Development and Commercialization
`Agreement Targeting Pulmonary Hypertension,” Red Orbit News,
`http://www.redorbit.com/modules/news/tools.php?tool:print&id:
`281787, 2 pages.
`Aristoffet al., “Synthesis ofbenzopyran prostaglandins, potent stable
`prostacyclin analogs, via an intermolecular mitsunobu reaction,” Tet-
`rahedron Letters, 1984, 25(36):3955-3958.
`Bein et al., “Cardiovascular and pulmonary effects of aerosolized
`prostacyclin andministration in severe respiratory failure using a
`ventilator nebulization system,” J. Cardiovascular Pharmacology,
`1996, 27, 583-586.
`Benedict et al., “Evidence-based pharmacologic management ofpul-
`monary arterial hypertension,” Clinical Therapeutics, 2007, 29,
`2134-2153.
`Bindl et a1 ., “Aero solised porstacyclin for pulmonary hypertension in
`neonates,” Archives of disease in childhood, Fetal and neonatal edi-
`tion, 1994, 71(3), F214-6.
`Booke et al., “Prostaglandins in Patients with Pulmonary Hyperten-
`sion: The Route of Administration,” Anesth. Analg., 1998, 86:917,
`Letter to the Editor.
`Byron, Peter R., “Drug Delivery Devices, Issues in Drug Develop-
`ment,” Proc. Am. Thorac. Soc., 2004, 1:321-328.
`Channick et al., “Safety and efficacy of inhaled trepro stinil as add-on
`therapy to bosentan in pulmonary arterial hypertension,” J. American
`College of Cardiology, 2006, 48, 1433-1437.
`Doyle et al., “Inhaled prostacyclin as a selective pulmonary vasodila-
`tor,” Anaesthesia and Intensive Care, Aug. 1996, 24(4):514-515.
`Dumas et al,. “Hypoxic pulmonary vasoconstriction,” General Phar-
`macology, 1999, 33, 289-297.
`Dworetz et al., “Survival of infants with persistent pulmonary hyper-
`tension without extracorporeal membrane oxygenation,” Pediatrics,
`1989, 84, 1-6.
`Ewert et al., “Aerosolized iloprost for primary pulmonary hyperten-
`sion,” New England Journal of Medicine, 2000, 343, 1421-1422.
`Ewert
`et
`al.,
`“Ilopro st
`als
`inhalative
`bzw.
`Intravenose
`langzeitbehandlung von patienten mit primarer pulmonaler
`hypertonie,” Z. Kardiol., 2000, 89, 987-999.
`Fink et al., “Use ofProstacyclin and its Analogues in the Treatment of
`Cardiovascular Disease,” Heart Disease, 1999, 1:29-40.
`Gessler et al., “Ultrasonic versus jet nebulization of iloprost in severe
`pulmonary hypertention,” Eur. Respir. J., 2001, 17, 14-19.
`Ghofrani et al., “Hypoxia- and non-hypoxia-related pulmonary
`hypertensioniEstablished and new therapies,” Cardiovascular
`Research, 2006, 72:30-40.
`
`Haraldsson et al., “Comparison of inhaled nitric oxide and inhaled
`aerosolized prostacyclin in the evaluation of heart transplant candi-
`dates with elevated pulmonary vascular resistance,” Chest, 1998,
`114, 780-786.
`Hoeper et al., “A comparison of the acute hemodynamic effects of
`inhaled nitric oxide and aerosolized iloprost in primary hyperten-
`sion,” J. American College of Cardiology, 2000, 35, 176-182.
`Hoeper et al., “Effects of inhaled nitric oxide and aerosolized iloprost
`in pulmonary veno-occlusive disease,” Respiratory Medicine, 1999,
`93, 62-70.
`Hoeper et al., “Long term treatment of primary pulmonary hyperten-
`sion with aerosolized iloprost, a prostacyclin analogue,” New
`England Journal of Medicine, 2000, 342, 1866-1870.
`Howarth, P.H., “Why particle size should affect clinical response to
`inhaled therapy,” Journal of Aerosol Medicine, 2001, 14 Supp. 1,
`S-27-S-34.
`Ichida et al., “Additive effects of beraprost on pulmonary vasodila-
`tion by inhaled nitric oxide in children with pulmonary hyperten-
`sion,” American Journal of Cardiology, 1997, 80, 662-664.
`Krause et al., “Pharmacokinetics and pharmacodynamics of the
`prostacyclin analogue iloprost in man,” Eur. J. Clin. Pharmacol.,
`1986, 30, 61-68.
`Lee et al., “Current strategies for pulmonary arterial hypertension,” J.
`Internal Medicine, 2005, 258, 199-215.
`Martin, John C., “Inhaled Form of Remodulin in the Pipeline,” http://
`www.phneighborhood.com/content/initheinews/archivei2320.
`aspx, ph Neighborhood, Oct. 28, 2005, 2 pages.
`Max et al., “Inhaled pro stacylin in the treatment ofpulmonary hyper-
`tension,” Eur. J. Pediatr., 1999, 158 Suppl 1, $23-$26.
`Nebu-Tec med. Produkte Eike Kern GmbH, VENTA-NEB®-ir A-I-
`C-I® Operating Instrutions, Sep. 2005.
`Olschewski et al. for the German PPH Study Group, “Inhaled ilopro st
`to treat severe pulmonary hypertensioniAn uncontrolled trial,”
`Annals of Internal Medicine, 2000, 132, 435-443.
`Olschewski et al., Aerosolized prostacyclin and iloprost in severe
`pulmonary hypertension,: Annals of Internal Medicine, 1996, 124,
`820 824.
`Olschewski et al., “Inhaled prostacyclin and iloprost in severe pul-
`monary hypertension secondary to lung fibrosis,” Am. Respir. Crit.
`Care Med., 1999, 160, 600-607.
`Olschewski et al., “Pharmacodynamics and pharmacokinetics of
`inhaled iloprost, aerosolized by three different devices, in severe
`pulmonary hypertension,” Chest, 2003, 124, 1294-1304.
`Olschewski et al., “Prostacyclin and its analogues in the treatment of
`pulmonary hypertension,” Pharmacology and Therapeutics, 2004,
`102,139-153.
`Olschewski et al., “Recovery from circulatory shock in severe pri-
`mary pulmonary hypertension (PPH) with aero solization ofiloprost,”
`Intensive Care Med., 1998, 24, 631-634.
`Pappert et al., “Aerosolized Prostacyclin Versus Inhaled Nitric Oxide
`in Children with Severe Acute Respiratory Distress Syndrome,”
`Anesthesiology, Jun. 1995, 82(6): 1507-151 1.
`Rigby, Jonathan, Aradigm Corporation, “Technological advances for
`success: Product pipeline in targeted pulmonary delivery,” Pulmo-
`nary Delivery Innovative Technologies Breathing New Life into
`Inhalable
`Therapeutics,
`ONdrugDelivery,
`http://www.
`ondrugdelivery.com/publications/Pulmonarypdf, 2006, 17-19.
`Sandifer et al., “Potent effects of aerosol compared with intravenous
`treprostinil on the pulmonary circulation,” J. Appl. Physiol., 2005,
`99:2363-2368.
`Santak et al., “Prostacyclin aerosol in an infant with pulmonary
`hypertension,” Eur. J. Pediatr., 1995, 154, 233-235.
`Soditt et al., “Improvement of oxygenation induced by aerosolized
`prostacyclin in a preterm infant with persistent pulmonary hyperten-
`sion of the newborn,” Intensive Care Med., 1997, 23, 1275-1278.
`Steffen et al., “The Effects of 15AU81, a Chemically Stable
`Prostacyclin Analog, on the Cardiovascular and Renin-Angiotensis
`Systems of Anesthetized Dogs,” Prostaglandins, Leukotrienes and
`Essential Fatty Acids, 1991, 43:277-286.
`Stricker et al., “Sustained improvement of performance and
`haemodynamics with long-term aerosolized prostacyclin therapy in
`severe pulmonary hypertension,” Schweiz Med. Wochenschr., 1999,
`129, 923-927.
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 2 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 2 of 24
`
`
`
`US 9,339,507 B2
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Van Heerden et al., “Inhaled aerosolized prostacyclin as a selective
`pulmonary vasodilator for the treatment of severe hypertension,”
`Anaesthesia and Intensive Care, 1996, 24, 87-90.
`Van Heerden et al., “Re: Delivery of inhaled aerosolized prostacyclin
`(IAP),” Anaesthesia and Intensive Care, 1996, 24, 624-625.
`Voswinckel et al., “Acute effects of the combination of sildenafil and
`inhaled treprostinil on haemodynamics and gas exchange in pulmo-
`nary hypertension,” Pulmonary Pharmacology & Therapeutics,
`2008, 21, 824-832.
`Voswinckel et al., “Favorable Effects of Inhaled Treprostinil in
`Severe Pulmonary Hypertension,” Journal of the American College
`of Cardiology, 2006, 48(8): 1672-1681.
`Voswinckel et al., “Inhaled Treprostinil for Treatment of Chronic
`Pulmonary Arterial Hypertension,” Annals of Internal Medicine, Jan.
`17,2006, 144(2):149-150.
`Walrnrath et al., “Effects ofinhaled versus intravenous vasodilators in
`experimental pulmonary hypertension,” Eur. Respir. J., 1997, 10,
`1084-1092.
`Wasserman et al., “Bronchodilator effects of prostacyclin (PGI2) in
`dogs and guinea pigs,” European Journal of Pharmacology, 1980, 66,
`53-63.
`Webb et al., “The use of inhaled aerosolized prostacyclin (IAP) in the
`treatment ofpulmonary hypertension secondary to pulmonary embo-
`lism,” Intensive Care Med., 1996, 22, 353-355.
`Wensel et al., “Effects of iloprost inhalation on exercise capacity and
`ventilator efficiency in patients with primary pulmonary hyperten-
`sion,” Circulation, 2000, 101, 2388-2392.
`Wetzel, R.C., “Aerosolized prostacyclin: in search of the ideal pul-
`monary vasodilator,” Anesthesiology, 1995, 82, 1315-1317.
`Zanen et al., “Optimal particle size for beta 2 agonist and
`anticholinergic aerosols in patients with severe airflow obstruction,”
`Thorax, 1996, 51, 977-980.
`Zanen et al., “The optimal particle size for B-adrenergic aerosols in
`mild asthmatics,” International Journal of Pharmaceutics, 1994, 107,
`2 1 1 -2 17.
`the Chemical Stable
`Findlay et al., “Radioimmunoassay for
`Prostacyclin Analog, 15AU81: a Preliminary Pharmacokinetics
`Study in the Dog,” Prostaglandins Leukot. Essent. Fatty Acids, Feb.
`1993, 48(2): 167-174.
`McNulty et al., “The Pharmacokinetics and Pharmacodynamics of
`the Prostacyclin Analog 15AU81 in the Anesthetized Beagle Dog,”
`Prostaglandins Leukot. Essent. Fatty Acids, Feb. 1993, 48(2):159-
`166.
`Saini et al., “Effect of Electrostatic Charge and Size Distributions on
`Respirable Aerosol Deposition in Lung Model,” Industry Applica-
`tions Conference, 2004, 39th IAS Annual Meeting, Conference
`Record ofthe 2004 IEEE Seattle, WA, Oct. 3-7, 2004, 2:948-952.
`Wittwer et al., “Inhalative Pre-Treatment of Donor Lungs Using the
`Aerosolized Prostacyclin Analog Iliprost Ameliorates Reperfusion
`Injury,” J. Heart Lung Transplant, 2005, 24:1673-1679.
`Agnew JE, Bateman RM, Pavia D, Clarke SW. (1984) Radionuclide
`demonstration of ventilatory abnormalities in mild asthma. Clinical
`Science; 66: 525-531.
`
`Annals of the International Commission on Radiological Protection
`(ICRP) vol. 28, No. 3, 1998, Publication 80, Radiation Dose to
`Patients from Radiopharmaceuticals.
`Blanchard, J.D., Cipolla, D., Liu, K., Morishige, R., Mudumba, S.,
`Thipphawong, J., Taylor, G., Warren, S., Radhakrishnan, R., Van
`Vlasselaer, R., Visor , G. and Starko, K. (2003) Lung Deposition of
`Interferon Gamma-1b following Inhalation via AERx® System vs.
`Respirgard IITM Nebulizer Proc. ATS Annual Meeting (Abstract
`A373), Seattle.
`Boyd, B., Noymer, P., Liu, K., Okikawa, J., Hasegawa, D., Warren, S.,
`Taylor, G., Ferguson, E., Schuster, J., Farr, S., and Gonda, I. (2004)
`Effect of Gender and Device Mouthpiece Shape on Bolus Insulin
`Aerosol Delivery Using the AERx Pulmonary Delivery System.
`Pharmaceutical Research. 21 (10) 1776-1782.
`Colthorpe P, Taylor G, Farr SJ. (1997) A comparison of two non-
`invasive methods for quantifying aerosol deposition in the lungs of
`rabbits. J. Aerosol Med.; 10:255.
`Farr et al., “Comparison of in vitro and in vivo efficiencies of a novel
`unit-dose liquid aerosol generator and a pressurized metered dose
`inhaler,” International Journal of Pharmaceutics, 2000, 198:63-70.
`Miller et al., “Standardisation of spirometry. Series ATS/ERS Task
`Force: Standardisation of Lung Function Testing” Eur Respir J 2005;
`26: 319-338.
`National Radiological Protection Board. Doses to Patients from
`Medical Radiological Examinations in Great Britain. (1986) Radio-
`logical Protection Bulletin No. 77.
`of
`Notes
`for Guidance
`on
`the Clinical Administration
`Radiopharmaceuticals and Use of Sealed Radioactive Sources.
`Administration of Radioactive Substances Advisory Committee
`(ARSAC) (Mar. 2006). ARSAC Secretariat, Chilton, Didcot, Oxon.
`OX11 0RQ.
`Publications of the International Commission on Radiological Pro-
`tection (ICRP) (1977) Recommendations of the International Com-
`mission on Radiological Protection 26.
`Pulmonary Delivery, ONdrugDelivery, 2006, 5 pages.
`Final OfficeAction dated Oct. 10, 2014 in U.S.Appl.No. 12/591,200.
`Non-Final Office Action dated Mar. 9, 2014 in US. Appl. \Io.
`12/591,200.
`Final OfficeAction dated Oct. 17, 2012 in U.S.Appl.No. 12/591,200.
`Final Office Action dated Dec. 22, 2011 in US. Appl.
`\Io.
`12/591,200.
`Non-Final Office Action dated Jan. 29, 2015 in US. Appl. \Io.
`13/120,015.
`Final Office Action dated Jul. 2, 2013 in US. Appl. No. 13/120,015.
`Non-Final Office Action dated Oct. 31, 2012 in US. Appl. \I0.
`13/ 120,015.
`Non-Final Office Action dated Dec. 30, 2014 in US. Appl. \Io.
`12/303,877.
`Final Office Action dated Nov. 4, 20 13 in US. Appl. No. 12/303,877.
`Non-Final Office Action dated Mar. 15, 2013 in US. Appl. \Io.
`12/303,877.
`Final Office Action datedAug. 1, 2012 in US. Appl. No. 12/303,877.
`Non-Final Office Action dated Oct. 11, 2011 in US. Appl. \Io.
`12/303,877.
`Scientific discussion for the approval of Ventavis, European Medi-
`cines Agency (EMEA), Oct. 20, 2004, 30 pages.
`
`
`
`* cited by examiner
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 3 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 3 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 1 0f 12
`
`US 9,339,507 B2
`
`120
`
`120
`
`E
`E.
`a)
`ill
`.E
`
`100
`
`D
`ED
`
`8
`
`a
`
`a
`
`a
`
`O
`2
`
`8
`
`.‘1‘
`
`.‘2
`
`S
`
`"
`
`80
`
`
`‘—
`
`n:
`D
`
`.“1'
`
`.‘2
`
`9-
`
`"°
`
`"
`
`‘°
`
`E
`.E.
`do
`0"
`.E
`
`100
`
`80
`
`D
`0
`
`8
`
`8
`
`o
`
`a
`
`D
`E
`
`8
`
`'E‘
`—
`a.
`E
`3—- <
`g
`m
`_
`"'
`
`3
`
`a
`
`O
`
`'E‘
`’N‘A’o‘
`--
`FQN
`E
`II
`II
`n
`555 3-—
`g
`$175153;
`._
`g
`” E E E
`5,0. 0. o.
`o “.3 9 9
`.oI—I—I—
`3 co m U)
`2333
`u. «av-co
`
`a
`
`3
`
`O
`
`::
`
`2
`
`0'
`
`"
`
`.“1
`
`.‘Z
`
`2
`
`"
`
`sanleA auuaseq ;o %
`
`san|eA auueseq }o 1%,
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 4 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 4 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 2 0f 12
`
`US 9,339,507 B2
`
`120
`
`80100
`time6“[min]
`
`
`
`20
`
`120
`
`100
`
`80
`
`
`
`time6ulmin]
`
`40
`
`20
`
`O
`
`SVOZ
`
`Sa02
`
`FIGURE2
`
`HR
`
`CO
`
`1
`
`0
`
`12
`
`
`
`1
`
`0
`
`u
`
`b
`
`F
`é
`
`v
`I
`
`e
`E
`
`g
`
`1
`
`12
`
`10
`
`7
`
`G
`
`120
`
`BO100
`
`60
`
`20
`
`120
`
`100
`
`80
`
`20
`
`0
`
`
`
`time[min]
`
`
`
`time[min]
`
`
`
`
`
`T30119Treprostinil(n=12)
`
`:4)
`
`-§—Placebo(n
`
`a
`E
`
`
`
`
`
`45ngTreprostinil(n=9)
`
`__.p_
`n
`E
`
`
`
`
`
`+60119Treprostinil(n=20)
`
`w
`A
`
`semen aunaseq 4o %
`
`sanleA auuaseq JO %
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 5 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 5 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 3 0f 12
`
`US 9,339,507 B2
`
`FIGURE3
`
`a"
`
`1
`
`60ug
`
`Placebo30pg
`
`
`
`Treprostinildose
`
`
`0
`
`-1000
`
`-2000
`
`-5000
`
`3000
`
`1000
`
`3000
`2000
`4000
`[u!w,%] semuuu ozL-o onv—aAd
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 6 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 6 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 4 0f 12
`
`US 9,339,507 B2
`
`Deadspace
`10-100
`
`
`
`011VentilationIPerfusionRatios
`
`1-10
`
`0.01-0.1
`
`g
`o"
`O
`
`;2.
`
`1:
`=3
`.c
`(I)
`
`FIGURE4
`
`1m
`
`am
`
`
`
`
`03:
`EC
`03ng
`%89
`(D'E%
`(U31;
`mZI—
`
`HIE
`
`0
`8
`
`O
`N
`
`O
`to
`
`O
`ID
`
`O
`1'
`
`O
`(‘0
`
`O
`N
`
`O
`\-
`
`O
`
`uogsnpad Bun-l JO weaned
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 7 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 7 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 5 0f 12
`
`US 9,339,507 B2
`
`[min] %treprostinil
`
`40
`
`20 time
`
`PVR
`
`{—iloprost
`
`FIGURE5
`
`anleA auuaseq JO %
`
`PVR
`
`5—iloprost—}treprostinil
`
`12
`
`=
`
`2
`
`0’
`
`a
`
`N
`
`(U
`
`SHIBA auglaseq JD %
`
`60
`
`
`
`20 time[min]
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 8 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 8 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 6 0f 12
`
`US 9,339,507 B2
`
`FIGURE 6
`
`11
`
`11
`
`11
`
`a
`
`11
`
`.-
`
`{- 7.5pgilopm-enin
`{- 7,5wlreprosfiriI-6m'n
`
`WR
`
`
`
`
`
`%ofbaselinevalue
`
`b 11
`
`—§- 7,5pgiloprost-6m’n
`—i—15pgh-eprodiri-6rri1
`
`
`
`
`
`%ofbaselinevalue
`
`c
`
`11
`
`-§- 7,5wilop'osl-6m'n
`-§-151-gtrepros11ri-arm
`
` “loofbaseline
`value
`
`r—v-fi—vfl—I—l—fi—fl—F—T'V'
`.10
`o
`1o
`20
`no
`40
`so
`so
`
`|—F—1—'I—'—I-_'—'l—|—F—"_P—T_r—1
`-10
`o
`1o
`20
`so
`40
`50
`so
`
`lime [nin]
`
`firm [m'n]
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 9 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 9 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 7 0f 12
`
`US 9,339,507 B2
`
`S
`
`3
`
`EE
`
`~
`8%
`
`0
`0
`
`{-iloprost5—treprostinil
`
`130
`
`120
`
`1
`1
`
`100
`
`9
`
`8
`
`
`
`time[min]
`
`o—,__.——fi——.——.——.——|o204060
`
`h
`
`-I-iloprost{—treprostinil
`
`‘E
`
`g
`g
`a;
`amen auuaseq ;o %
`
`8
`
`3
`
`g
`
`0204060
`
`%
`9.
`
`f-iloprosti—lreprostinil
`
`110
`
`D
`
`H
`
`7
`
`FIGURE7
`
` PVR
`
`E:5
`eD.
`2,4
`
`-§—iloprost
`
`..F
`
`S
`8
`g
`anIBA auuaseq 1o 0/.
`
`r~
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 10 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 10 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 8 0f 12
`
`US 9,339,507 B2
`
`FIGURE 8
`
`t limbo
`
`-Q— Sougtmpmsfinil
`—W— Gowtmproetinll
`
`
`
`1
`1
`
`a,
`:1
`
`T;
`w 11
`.5
`3 ‘
`1»
`N
`.D
`I.—
`O
`.\°
`
`1
`
`a,
`:1
`
`E “
`0
`E 1
`a
`1n
`I!
`.9
`H-
`O
`°\°
`
`1
`
`11
`
`1
`
`0
`2
`I!
`>
`U
`.E
`a
`10
`I!
`.0
`
`‘6
`=\°
`
`1
`
`11
`
`41
`2
`N
`> 1
`41
`E
`T:
`0)
`N
`.0
`
`‘6
`a\°
`
`'_l_'_l_"-T—"“1_'_I’_'_l_'—I—'-T_'_I"_I WW
`0
`m
`40
`so
`so
`100
`120
`140
`160
`130
`o
`20
`40
`so
`so
`100
`120
`140
`160
`100
`
`time [11in]
`
`CO
`
`
`
`1 1
`
`O
`1
`_:
`N
`> M
`0
`.E
`3 '
`U!
`N
`.0
`
`‘6
`.,\°
`
`time [nin]
`
`SAP
`
`
`0
`20
`40
`so
`80
`100
`120
`140
`160
`180
`0
`20
`40
`E)
`80
`100
`1Z1
`140
`1B)
`180
`
`fine [m'n]
`
`Sa02
`
`firre [nin]
`
`Sv02
`
`1
`
`11
`
`0
`2
`I!
`> 1
`d)
`.5
`3
`III
`I!
`.D
`
`'6
`o\°
`
`0
`
`20
`
`40
`
`60
`
`80
`
`100
`
`120
`
`140
`
`160
`
`180
`
`WW
`0
`20
`40
`60
`60
`100
`120
`140
`1d)
`180
`
`time [nin]
`
`firre [nin]
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 11 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 11 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 9 0f 12
`
`US 9,339,507 B2
`
`FIGURE 9
`
`PVR
`
`PAP
`
`
`
`
`
`«9‘909‘?) 0.96;
`
`p99
`
`69'‘9
`
`9'99
`
`a? -1
`O
`CD .2
`<
`
`-2
`
`-3
`
`-3
`
`a? '1
`0
`CD
`< '1
`
`-2
`
`2
`
`Q
`Q
`Q
`Q
`Q
`Q
`
`5°?
`«9‘?
`9°?
`5°?
`19‘}
`9°?
`
`C? .
`O
`CD .
`<
`
`
`
`a? '1
`0
`CD
`< -1
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 12 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 12 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 10 0f 12
`
`US 9,339,507 B2
`
`FIGURE 10
`
`o
`2
`N
`>
`o 1
`5
`E
`1n
`1v
`.O
`I-
`o
`e\°
`
`1
`
`1
`
`1
`
`0
`21
`a
`> 11
`0
`E
`3 1
`W
`B
`u«5
`°\o
`
`7
`
`o
`
`20
`
`40
`
`so
`
`an
`
`100
`
`120
`
`140
`
`1m 130
`
`o
`
`20
`
`40
`
`so
`
`an
`
`100
`
`120
`
`140
`
`160
`
`130
`
`firm [m'n]
`
`firm [nin]
`
`31.1.:
`
`o
`.3.
`N
`> 1
`o
`.5
`'6
`«n
`«1
`.O
`I-
`O
`a?
`
`1
`
`11
`
`1
`
`d3
`a
`“1
`>
`U
`.5
`'5
`W
`N.O
`'6
`°\°
`
`11
`
`
`o
`
`20
`
`40
`
`so
`
`an
`
`100
`
`120
`
`140
`
`150
`
`100
`
`$1509TRE-1ewses
`T15ugTRE-9pdses
`3-15ugTRE-3ptlses
`—Q—15pgTRE—2pdses
`-T-15ugTRE-1pdse
`o
`20
`40
`so
`
`an
`
`100
`
`120
`
`140
`
`150
`
`130
`
`firm [m'n]
`
`firm [m'n]
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 13 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 13 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 11 0f 12
`
`US 9,339,507 B2
`
`FIGURE 11
`
`
`
`
`
`1
`
`0
`a:
`<
`
`J' ! '1'
`
`'1'
`
`
`
`fi—I—fl—fi—l—
`
`0
`m
`< 1
`
`a
`—I—l—fi—fij-
`
`7% 7% 7% 7
`
`1
`
`7% 7% 7% 7% 7%
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 14 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 14 of 24
`
`
`
`US. Patent
`
`May 17, 2016
`
`Sheet 12 0f 12
`
`US 9,339,507 B2
`
`100120140160180200220240
`
`OV
`
`' ON O
`
`EE
`
`I—I
`
`C
`.2
`E
`E
`.5
`"-O
`'cC
`a:
`3
`8 zN
`a:
`8 .§4.0
`
`(\l
`‘—
`LU
`1x
`D
`(D
`_
`LL
`
`
`
`—i—30pgTRE(n=4)
`
`
`
`TRE(n=2):67—60pgTRE(n=4)—E—90pgTRE(n=1)+120pg
`
`
`
`of)
`
`N
`
`\-
`
`O
`
`[nu/Bu] uonenuaouoo ewse|d Hugsmden
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 15 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 15 of 24
`
`
`
`US 9,339,507 B2
`
`1
`TREPROSTINIL ADMINISTRATION BY
`INHALATION
`
`CROSS REFERENCE TO RELATED
`APPLICATIONS
`
`The present application is a Divisional of US. application
`Ser. No. 12/591,200, filed Nov. 12, 2009, which is a Continu-
`ation of US. application Ser. No. 11/748,205, filed May 14,
`2007, which claims priority to US. provisional application
`No. 60/800,016 filed May 15, 2006, which are incorporated
`herein by reference in their entirety.
`
`FIELD OF THE INVENTION
`
`The present application relates to methods and kits for
`therapeutic treatment and, more particularly, to therapeutic
`methods involving administering treprostinil using a metered
`dose inhaler and related kits.
`
`BACKGROUND OF THE INVENTION
`
`All blood is driven through the lungs via the pulmonary
`circulation in order, among other things, to replenish the
`oxygen which it dispenses in its passage around the rest ofthe
`body via the systemic circulation. The flow through both
`circulations is in normal circumstances equal, but the resis-
`tance offered to it in the pulmonary circulation is generally
`much less than that of the systemic circulation. When the
`resistance to pulmonary blood flow increases, the pressure in
`the circulation is greater for any particular flow. The above
`described condition is referred to as pulmonary hypertension
`(PH). Generally, pulmonary hypertension is defined through
`observations of pressures above the normal range pertaining
`in the majority of people residing at the same altitude and
`engaged in similar activities.
`Pulmonary hypertension may occur due to various reasons
`and the different entities of pulmonary hypertension were
`classified based on clinical and pathological grounds in 5
`categories according to the latest WHO convention, see e.g.
`Simonneau G., et al. J. Am. Coll. Cardiol. 2004; 43(12 Suppl
`S):5S-12S. Pulmonary hypertension can be a manifestation
`of an obvious or explicable increase in resistance, such as
`obstruction to blood flow by pulmonary emboli, malfunction
`of the heart’s valves or muscle in handling blood after its
`passage through the lungs, diminution in pulmonary vessel
`caliber as a reflex response to alveolar hypoxia due to lung
`diseases or high altitude, or a mismatch of vascular capacity
`and essential blood flow, such as shunting of blood in con-
`genital abnormalities or surgical removal of lung tissue. In
`addition, certain infectious diseases, such as HIV and liver
`diseases with portal hypertension may cause pulmonary
`hypertension. Autoimmune disorders, such as collagen vas-
`cular diseases, also often lead to pulmonary vascular narrow-
`ing and contribute to a significant number of pulmonary
`hypertension patients. The cases of pulmonary hypertension
`remain where the cause of the increased resistance is as yet
`inexplicable are defined as idiopathic (primary) pulmonary
`hypertension (iPAH) and are diagnosed by and after exclu-
`sion of the causes of secondary pulmonary hypertension and
`are in the majority of cases related to a genetic mutation in the
`bone morphogenetic protein receptor-2 gene. The cases of
`idiopathic pulmonary arterial hypertension tend to comprise a
`recognizable entity of about 40% ofpatients cared for in large
`specialized pulmonary hypertension centers. Approximately
`65% of the most commonly afflicted are female and young
`adults, though it has occurred in children and patients over 50.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`2
`
`Life expectancy from the time of diagnosis is short without
`specific treatment, about 3 to 5 years, though occasional
`reports of spontaneous remission and longer survival are to be
`expected given the nature of the diagnostic process. Gener-
`ally, however, disease progress is inexorable via syncope and
`right heart failure and death is quite often sudden.
`Pulmonary hypertension refers to a condition associated
`with an elevation of pulmonary arterial pressure (PAP) over
`normal levels. In humans, a typical mean PAP is approxi-
`mately 12-15 mm Hg. Pulmonary hypertension, on the other
`hand, can be defined as mean PAP above 25 mmHg, assessed
`by right heart catheter measurement. Pulmonary arterial pres-
`sure may reach systemic pressure levels or even exceed these
`in severe forms of pulmonary hypertension. When the PAP
`markedly increases due to pulmonary venous congestion, i.e.
`in left heart failure or valve dysfunction, plasma can escape
`from the capillaries into the lung interstitium and alveoli.
`Fluid buildup in the lung (pulmonary edema) can result, with
`an associated decrease in lung function that can in some cases
`be fatal. Pulmonary edema, however, is not a feature of even
`severe pulmonary hypertension due to pulmonary vascular
`changes in all other entities of this disease.
`Pulmonary hypertension may either be acute or chronic.
`Acute pulmonary hypertension is often a potentially revers-
`ible phenomenon generally attributable to constriction of the
`smooth muscle ofthe pulmonary blood vessels, which may be
`triggered by such conditions as hypoxia (as in high-altitude
`sickness), acidosis, inflammation, or pulmonary embolism.
`Chronic pulmonary hypertension is characterized by major
`structural changes in the pulmonary vasculature, which result
`in a decreased cross-sectional area of the pulmonary blood
`vessels. This may be caused by, for example, chronic hypoxia,
`thromboembolism, collagen vascular diseases, pulmonary
`hypercirculation due to left-to-right shunt, HIV infection,
`portal hypertension or a combination of genetic mutation and
`unknown causes as in idiopathic pulmonary arterial hyper-
`tension.
`
`Pulmonary hypertension has been implicated in several
`life-threatening clinical conditions, such as adult respiratory
`distress syndrome (“ARDS”) and persistent pulmonary
`hypertension of the newborn (“PPHN”). Zapol et al., Acute
`Respiratory Failure, p. 241-273, Marcel Dekker, New York
`(1985); Peckham, J. Ped. 9321005 (1978). PPHN, a disorder
`that primarily affects full-term infants, is characterized by
`elevated pulmonary vascular resistance, pulmonary arterial
`hypertension, and right-to-left shunting of blood through the
`patent ductus arteriosus and foramen ovale of the newbom’s
`heart. Mortality rates range from 12-50%. Fox, Pediatrics
`59:205 (1977); Dworetz, Pediatrics 84: 1(1989). Pulmonary
`hypertension may also ultimately result in a potentially fatal
`heart condition known as “cor pulmonale,” or pulmonary
`heart disease. Fishman, “Pulmonary Diseases and Disorders”
`2’” Ed., McGraw-Hill, New York (1988).
`Currently, there is no treatment for pulmonary hyperten-
`sion that can be administered using a compact inhalation
`device, such as a metered dose inhaler.
`
`SUMMARY OF THE INVENTION
`
`One embodiment is a method of delivering to a subject in
`need thereof a therapeutically effective amount of treprosti-
`nil, or trepro stinil derivative or a pharmaceutically acceptable
`salt thereof comprising administering to the subject a thera-
`peutically effective amount of the treprostinil or treprostinil
`derivative or a pharmaceutically acceptable salt thereofusing
`a metered dose inhaler.
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 16 of 24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1001, p. 16 of 24
`
`
`
`US 9,339,507 B2
`
`3
`Another embodiment is a method for treating pulmonary
`hypertension comprising administering to a subject in need
`thereof treprostinil or its derivative, or a pharmaceutically
`acceptable salt thereof using a metered dose inhaler.
`Yet another embodiment is a kit comprising a metered dose
`inhaler containing a pharmaceutical formulation comprising
`treprostinil or treprostinil derivative, or a pharmaceutically
`acceptable salt thereof.
`And yet another embodiment is a kit for treating pulmo-
`nary hypertension in a subject, comprising (i) an effective
`amount of treprostinil or its derivative, or a pharmaceutically
`acceptable salt thereof;
`(ii) a metered dose inhaler; (iii)
`instructions for use in treating pulmonary hypertension.
`Administration oftreprostinil using a metered dose inhaler
`can provide patients,
`such as pulmonary hypertension
`patients, with a high degree of autonomy.
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 pulmonary and systemic changes in hemodynamics
`following the inhalation of placebo (open circles), 30 pg
`treprostinil (triangles), 45 pg treprostinil (squares) or 60 pg
`TREprostinil (black circles) applied by a Metered Dose
`Inhaler (MDI-TRE). A single short inhalation of treprostinil
`induced sustained reduction of PAP and PVR that outlasted
`
`the observationperiod of 120 minutes at doses of45 and 60 pg
`MDI-TRE. Systemic arterial pressure and resistance were not
`significantly affected. PAP:mean pulmonary artery pressure;
`PVR:pulmonary vascular resistance; SAP:mean systemic
`arterial pressure; SVR:systemic vascular resistance. Data are
`given as mean valueistandard error of the mean (SEM).
`FIG. 2 presents hemodynamic changes induced by the
`inhalation of placebo (open circles), 30 pg treprostinil (tri-
`angles), 45 pg treprostinil (squares) or 60 pg treprostinil
`(black circles) applied by a metered dose inhaler. Tr